Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$5.6B
20M shares
52-week range
$161.82 – $326.63
70% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
20.8
EV / FCF (TTM)
46.9
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
www.ligand.comNo one on the platform currently holds LGND.
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2025-12-31 | 4,207 | $795.4K |
| Renaissance Technologiesas of 2024-09-30 | 3,000 | $300.3K |
| Execution date | Ratio |
|---|---|
| 2010-11-19 | 1-for-6reverse |
No one on the platform has traded LGND yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 2.9% | 3.4% | — | — | — | |
| Rev. Growth % | 60.4% | 10.4% | ||||
| Profit Margin % | 46.4% | 18.1% | 67.6% | |||
| Free Cash Flow Margin % | 18.2% | 30.3% | 32.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +8.3% on the P/E track.
At today's price, your expected annual return is +15.5% on the P/E track.
At today's price, your expected annual return is +21.9% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $291M | +10.1% | $9.32 | $9.11–$9.53 | 29.7× | 7 |
| 2027 | $384M | +32.2% | $12.11 | $11.78–$12.75 | 22.8× | 7 |
| 2028 | $456M | +18.7% | $14.54 | $13.87–$15.35 | 19.0× | 5 |
| 2029 | $551M | +21.0% | $16.36 | $14.88–$17.91 | 16.9× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $2.01 | $2.37 | +17.9% |
| 2026-05-14 | $1.84 | $1.63 | -11.4% |
| 2026-02-26 | $1.46 | $2.02 | +38.4% |
| 2025-11-06 | $1.97 | $3.09 | +56.9% |
| 2025-08-07 | $1.42 | $1.60 | +12.7% |
| 2025-05-08 | $1.21 | $1.33 | +9.9% |
| 2025-02-27 | $1.37 | $-1.64 | -219.7% |
| 2024-11-07 | $1.35 |
| $-0.39 |
| -128.9% |
| $9.0B |
| — |
| DYNDyne Therapeutics, Inc. | $18.20 | -1.69% | $3.4B | — |
| MIRMMirum Pharmaceuticals, Inc. | $95.73 | -1.05% | $5.8B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
These Two Healthcare Stocks Hit Key Milestones Today – Why Is Wall Street Bullish On Them? $OBIO $LFST $MDT $LGND https://stocktwits.com/news/equity/markets/why-did-obio-lfst-stocks-hit52-week-highs/cZtaSjBRJ60
View on StockTwits ↗
Rad204 starting to show really good efficacy at 90 mci and that’s only at 45% the lutetium 177 strength of Pluvicto and Lutathera they dose at 200 mci of lutetium 177… a few more partials at 90mci and their ORR will be legendary. $IOVA $RADX $LGND and $CATX all in the hardest treatable cancer patients in Lung Cancer…
View on StockTwits ↗
@Rungreen I know more Marines than you do. My old man was one in Vietnam from 1968-1970 or so. You are patently wrong on the CCP and the Muslim faith. Please study the Abrahamic religions (Islam, Christianity, and Judaism). Otherwise I am giving up on $TNXP $LGND $LEGN And Chicago’s own $ABBV 🐻 💪 🇨🇳 🇵🇱 🇺🇸 ⚡️ 🚀 Your move, sir ✅
View on StockTwits ↗
$LGND: XOMA Acquisition Closed https://buff.ly/N4o5pSE
View on StockTwits ↗
https://www.marketbeat.com/earnings/reports/2026-8-6-ligand-pharmaceuticals-incorporated-stock/ $LGND Ligand Pharmaceuticals Earnings Tran
View on StockTwits ↗
$LGND Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $2.42 up 868.00% YoY • Reported revenue of $63.69M up 33.73% YoY • Ligand Pharmaceuticals is reaffirming its 2026 full-year revenue guidance and is raising the low end of its adjusted earnings per diluted share guidance range to approximately $9.00 to $9.50.
View on StockTwits ↗
$BVAXF $BIOV.CSE $BVAXF is pursuing an out-licensing model, which could reduce internal commercialization requirements. The tradeoff is dependence on partner interest, deal structure and milestone execution. $LGND $RPRX $MRNA
View on StockTwits ↗
$LGND – WED: Fell Below the Round-$300 Support and Triggered a 3rd Sell Signal +38.7% 7:30 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/wed-7-15-lgnd-fell-below-the-round-300-support-and-triggered-a-3rd-sell-signal-38-7/
View on StockTwits ↗$LGND – TUE: Continued Above Average Volume Declines Today – a Break Below $300 Is a Sell Signal 8:30 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/mon-7-13-oii-decent-gain-yet-closed-off-of-the-high-and-volume-was-20-2/
View on StockTwits ↗$LGND – MON: Did Close Below Its 10 DMA – a Break of $300 Would Be a Sell Signal 8:30 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/mon-7-13-lgnd-did-close-below-its-10-dma-a-break-of-300-would-be-a-sell-signal/
View on StockTwits ↗
$XOMA / $LGND – Possible Completion, Shareholder Vote XOMA
View on StockTwits ↗
@activehybrid @VelorexCapital Shane needs to step down, he's had too much controversy aside from his failures to get this drug approved. Another issue I forgot to mention is the lack of funding. We're looking at massive dilution to have this distributed once it's approved, less than 30 million in the coffers as of this moment, which is nothing when it comes to commercialization ramp up. Might as well partner with another company to have it distributed. Nothing wrong with a royalty model either, it's what has propelled $LGND as far as it's gone.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.